Latest Tax Incentives News

Nyrada Inc. posted a significant $2.46 million loss for H1 FY25, driven by increased R&D spend, while advancing its lead drug NYR-BI03 into first-in-human trials following regulatory approval.

Zelira Therapeutics has received a $1.15 million cash refund from the Australian Government’s R&D Tax Incentive Scheme, bolstering its working capital to advance clinical development and business operations.

Ausmon Resources Limited has launched a Share Purchase Plan offering shareholders shares at an 8.6% discount, with potential tax credits for Australian investors. The move aims to strengthen the company’s balance sheet and fund exploration activities.

SG Fleet Group reported robust first-half 2025 results, driven by strong delivery volumes and revenue growth across Australia, New Zealand, and the UK, despite ongoing pressures in the used vehicle market.

SG Fleet Group reported a solid $41.1 million NPAT for the first half of 2025, driven by strong disposal volumes and fleet growth across Australia, New Zealand, and the UK. While profit dipped from last year, the company anticipates normalization in the second half.

Neurizon Therapeutics reported a sharp rise in half-year losses to $7.28 million but marked significant progress with its lead drug NUZ-001 entering a major ALS clinical trial and securing critical regulatory designations.

Chalice Mining has achieved a major metallurgical breakthrough at its Gonneville Project, enabling the production of saleable copper and nickel concentrates from low-grade ores without costly hydrometallurgical processing. This innovation promises to significantly reduce capital and operating costs while improving project margins.

Carly Holdings Limited has agreed to merge its car subscription operations with Carbar Holdings in a $3.8 million deal, aiming to create a larger, more competitive player in Australia’s growing car subscription sector.

Cycliq Group Limited reported an 18% revenue increase to $2.9 million for the half-year ending December 2024, driven by higher transaction values and a revamped marketing strategy, despite a modest net loss of $211,214.

Echo IQ has secured a $1.26 million refund under the Australian Government's R&D Tax Incentive, reinforcing its commitment to AI-driven solutions for structural heart disease detection.

Argenica Therapeutics reported a 16% reduction in half-year losses to $1.19 million, buoyed by a 29% increase in other income largely from R&D tax incentives, as it advances its neuroprotective drug development.

Spacetalk Ltd has secured a $428,853 R&D tax rebate from the Australian Taxation Office, reinforcing its commitment to innovation while reporting a 16% increase in Annual Recurring Revenue and significant cost reductions.